key: cord-0290380-zlkq1bj7
authors: McMahan, Katherine; Giffin, Victoria; Tostanoski, Lisa H.; Chung, Benjamin; Siamatu, Mazuba; Suthar, Mehul S.; Halfmann, Peter; Kawaoka, Yoshihiro; Piedra-Mora, Cesar; Martinot, Amanda J.; Kar, Swagata; Andersen, Hanne; Lewis, Mark G.; Barouch, Dan H.
title: Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters
date: 2022-01-03
journal: bioRxiv
DOI: 10.1101/2022.01.02.474743
sha: a490a60b5b1d3f06e715b04c68efc7ce6ab7ddb5
doc_id: 290380
cord_uid: zlkq1bj7

The SARS-CoV-2 Omicron (B.1.1.529) variant has proven highly transmissible and has outcompeted the Delta variant in many regions of the world1. Early reports have also suggested that Omicron may result in less severe clinical disease in humans. Here we show that Omicron is less pathogenic than prior SARS-CoV-2 variants in Syrian golden hamsters. Infection of hamsters with the SARS-CoV-2 WA1/2020, Alpha, Beta, or Delta strains led to 4-10% weight loss by day 4 and 10-17% weight loss by day 6, as expected2,3. In contrast, infection of hamsters with two different Omicron challenge stocks did not result in any detectable weight loss, even at high challenge doses. Omicron infection still led to substantial viral replication in both the upper and lower respiratory tracts and pulmonary pathology, but with a trend towards higher viral loads in nasal turbinates and lower viral loads in lung parenchyma compared with WA1/2020 infection. These data suggest that the SARS-CoV-2 Omicron variant may result in more robust upper respiratory tract infection but less severe lower respiratory tract clinical disease compared with prior SARS-CoV-2 variants.

3 two Omicron challenge stocks and assessed clinical disease, viral loads, and histopathology in hamsters.

We generated two independent SARS-CoV-2 Omicron stocks in VeroE6-TMPRSS2 cells inoculated with nasal swabs from Omicron-infected individuals. Omicron Stock 1 had a titer of 2.3x10 9 TCID50/ml and 2.5x10 7 PFU/ml in VeroE6-TMPRSS2 cells (EPI_ISL_7171744; Mehul Suthar, Emory University). Omicron Stock 2 had a titer of 2.3x10 8 TCID50/ml and 3. Note that TCID50 titers in VeroE6-TMPRSS2 cells are approximately 100-fold higher than previously reported TCID50 titers in VeroE6 cells. Infected hamsters showed a mean reduction of 4-10% of body weight by day 4 (Fig. 1a) and 10-17% of body weight by day 6 ( Fig. 1b) 2, 3 .

One animal infected with WA1/2020 reached the 20% weight loss criteria for humane euthanization, but the rest of the hamsters recovered their body weights by approximately day 10.

Additional groups of hamsters (N=4/group) were concurrently inoculated by the intranasal route with 100 ul of undiluted, 1:10 dilution, or 1:100 dilution of Omicron Stock 1 or Stock 2. For Stock 1, the challenge doses were 2.3x10 8 TCID50 (2.5x10 6 PFU), 2.3x10 7 TCID50 (2.5x10 5 PFU), and 2.3x10 6 TCID50 (2.5x10 4 PFU). Hamsters inoculated with Omicron Stock 1 showed a mean reduction of -1%, -2%, and 1% of body weight by day 4 for these challenge doses, respectively (Fig. 1c) . For Stock 2, the challenge doses were 2.3x10 7 4 TCID50 (3.8x10 5 PFU), 2.3x10 6 TCID50 (3.8x10 4 PFU), and 2.3x10 5 TCID50 (3.8x10 3 PFU).

Hamsters inoculated with Omicron Stock 2 showed a mean reduction of 0%, 0%, and 1% of body weight by day 4 for these challenge doses, respectively (Fig. 1d) . Additional follow-up time beyond day 4 did not reveal any late weight loss (data not shown). These data demonstrate that two independent SARS-CoV-2 Omicron stocks did not lead to clinical weight loss in hamsters, even when inoculated at high doses.

We next assessed tissue viral loads on day 4 following infection of hamsters with 5x10 4 PFU WA1/2020 (N=13), 5x10 4 PFU Beta (N=11), and the titration of Omicron Stock 1 described above (N=12). Levels of E subgenomic RNA (sgRNA) and N genomic RNA (gRNA)

were assessed by RT-PCR in lungs and nasal turbinates [8] [9] [10] . In lung tissue, hamsters infected with WA1/2020, Beta, and Omicron had a median of 9.07, 9.55, and 8.33 log sgRNA copies/g tissue. Median levels of lung sgRNA were 0.74 log lower in Omicron-infected hamsters compared with WA1/2020-infected hamsters (P=0.004, two-tailed Mann-Whitney test; Fig. 2a ).

In nasal turbinates, hamsters infected with WA1/2020, Beta, and Omicron had a median of 6.35, 7.34, and 8.25 log sgRNA copies/g tissue. Median levels of nasal turbinate sgRNA were 1.90 log higher in Omicron-infected hamsters compared with WA1/2020-infected hamsters (P=0.05, two-tailed Mann-Whitney test; Histopathology of lung tissue on day 4 following infection with WA1/2020 or Omicron revealed multifocal areas of interstitial inflammation and consolidation associated with bronchioles ( Fig. 3a) . Bronchiolar epithelium showed degeneration, loss of cilia, loss of nuclear polarity, and sloughing in both WA1/2020 and Omicron infected hamsters (Fig. 3b) . Vascular inflammatory infiltrates and endothelialitis were observed in both WA1/2020 and Omicron infected hamsters (Extended Data Fig. 3 ).

Our data demonstrate that the SARS-CoV-2 Omicron variant infects Syrian golden hamsters over a broad range of challenge doses. However, Omicron infection did not result in detectable weight loss, even at doses that were 100-times higher than the doses of WA1/2020, Alpha, Beta, and Delta that led to substantial weight loss. The consistency of these findings with two independent Omicron challenge stocks suggests the generalizability of these conclusions.

Omicron infection led to robust viral replication in both the upper and lower respiratory tracts, but with higher viral loads in nasal turbinates and lower viral loads in lung compared with WA1/2020. These data suggest that Omicron infection may lead to increased upper respiratory tract disease but reduced lower respiratory tract disease. Nevertheless, Omicron infection still led to lung pathology, including patchy consolidation, bronchiolar epithelial degeneration, and endothelialitis.

Our findings in hamsters are consistent with preliminary reports suggesting that Omicron 

The WA1/2020 (USA-WA1/2020; BEI Resources NR-5228), Alpha (B. cells.

SARS-CoV-2 N gene genomic RNA (gRNA) and E gene subgenomic RNA (sgRNA)

was assessed by reverse transcription polymerase chain reactions (RT-PCR) using primers and probes as previously described. [8] [9] [10] Standards were generated by first synthesizing a gene fragment of the genomic N gene or subgenomic E gene. 9 The gene fragments were subsequently cloned into a pcDNA3.1+ expression plasmid using restriction site cloning (Integrated DNA Technologies). The inserts were in vitro transcribed to RNA using the AmpliCap-Max T7 High

Yield Message Maker Kit (CellScript). Log dilutions of the standard were prepared for RT-PCR assays ranging from 1x10 10 copies to 1x10 -1 copies. Viral loads were quantified from lung tissue as follows; total RNA was extracted on a QIAcube HT instrument using the RNeasy 96 QIAcube HT Kit according to manufacturer's specifications (Qiagen). Standard dilutions and extracted total RNA from samples were reverse transcribed using SuperScript VILO Master Mix (Invitrogen) according to manufacturer's specifications. A Taqman custom gene expression assay (Thermo Fisher Scientific) was designed using the sequences targeting the E gene sgRNA. 9

The sequences for the custom assay were as follows, forward primer, sgLeadCoV2.Fwd: for 20 seconds, then 45 cycles of 95ºC for 1 second and 60ºC for 20 seconds. Standard curves were used to calculate subgenomic RNA copies and copy number was normalized to the input weight of lung tissue (copies/g); the quantitative assay sensitivity was 100 copies per gram.

Tissues were fixed in freshly prepared 4% paraformaldehyde for 24 hours, transferred to 70% ethanol, paraffin embedded within 7 to 10 days, and block sectioned at 5 µm. Slides were baked for 30 to 60 min at 65 °C and then deparaffinized in xylene and rehydrated through a series of graded ethanol to distilled water. Slides were stained with hematoxylin and eosin. Blinded assessment of tissue pathology was performed by a veterinary pathologist (AJM).

Analysis of virologic and body weight data was performed using GraphPad Prism 9.1.2 (GraphPad Software). Comparison of data between groups was performed using two-sided Mann-Whitney tests. P values of less than 0.05 were considered significant.

14 Extended Data Figure 

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv

Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Animal models for COVID-19

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

The authors acknowledge NIH grant CA260476, the Massachusetts Consortium for Pathogen Readiness, the Ragon Institute, and the Musk Foundation (D.H.B.).

All data are available in the manuscript or the supplementary material. Correspondence and requests for materials should be addressed to D.H.B. (dbarouch@bidmc.harvard.edu).

The authors report no financial conflicts of interest.

This study was designed by DHB. Omicron challenge stocks were prepared by MS and YK.Animal work was performed by HA and MGL. Virologic assays were performed and analyzed by KM, VG, LHT, BC, and MS. Histopathology was performed by CPM and AJM.